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1. ABBREVIATIONS  
 
ACE  angiotensin-converting enzyme 
ACR  albumin-creatinine ratio 
APC  argon plasma coagulation 
ARB  angiotensin II receptor blocker 
CAI  Colitis Activity Index 
CD  Crohn’s disease 
CDAI  Crohn’s Disease Activity Index 
CRC  colorectal cancer 
CRF  chronic renal failure 
DM  diabetes mellitus 
ESR  erythrocyte sedimentation rate 
GAVE gastric antral vascular ectasia 
GIT   gastrointestinal tract 
H-B  Harvey-Bradshaw 
HCT  hematocrit 
HPLC high-performance liquid chromatography 
hs-CRP high-sensitivity C reactive protein 
HT  hypertension 
IBD  inflammatory bowel disease 
IT  immunoturbidimetry 
MAU  microalbuminuria 
MDRD Modification of Diet in Renal Disease 
OPP  oetrogen-progesteron product 
PLT  platelet count 
RBC  red blood cell 
TG  triglyceride 
TL   telangiectatic lesion 
UC  ulcerative colitis 
WBC  white blood cell 
 3 
2. INTRODUCTION AND AIMS 
 
1. For clinicians, estimation of activity in inflammatory bowel disease (IBD) represents a 
difficult problem. In previous studies, urinary albumin determined by an immunological 
method (immunoturbidimetry /IT/) has been found to be a useful and simple marker of IBD 
activity. We aimed to compare urinary albumin excretion by means of a new high-
performance liquid chromatography (HPLC) method andIT in both groups of IBD patients 
(Crohn’s disease /CD/ and ulcerative colitis /UC/) and to find associations of these parameters 
with clinical activity of the disease. 
 
2. Microalbuminuria (MAU) is an early marker of diabetic nephropathy. It has been proved to 
be a risk factor for atherosclerosis, for cardiovascular diseases and mortality. It also predicts 
all-cause mortality. In previous studies, increased albuminuria has also been detected in 
individuals with different locations of cancers. There was no correlation between MAU and 
colorectal cancer (CRC) at all. We aimed to investigate the urinary albumin of the patients 
with CRC by means of two different methodologies (IT and HPLC) and to find correlations 
between the results and the stage of CRC. 
 
3. Gastric antral vascular ectasia (GAVE) as a vascular malformation is a rare cause of upper 
gastrointestinal bleeding. It is an important antral lesion because it can cause an occult chronic 
or severe acute bleeding. In the most cases it can be seen in cirrhotic patients but it is also 
more common in patients with chronic renal failure (CRF) together with isolated 
telangiectatic lesions (TL). The most reliable treatment method is argon plasma coagulation 
(APC). We aimed to investigate the prevalence of GAVE, to describe its appearance in 
patients with CRF and its therapy using oestrogen-progesteron product (OPP).  
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3. PATIENTS AND METHODS 
 
1. We studied 207 outpatients with IBD (107 with CD, 100 with UC) between August 2007 
and September 2008. The diagnosis of IBD was confirmed on the basis of endoscopy and 
histology. We excluded patients who suffered from diseases, conditions or were using 
medications which can modify the rate of urinary albumin excretion. After selection, a cross-
sectional study with 60 CD patients and with 57 UC patients was performed and these patients 
were treated by usual treatment in IBD. As controls, urine specimens were obtained from 22 
healthy medical students and health care professional volunteers. Routine laboratory 
measurements and first morning urine samples analyses by means of IT and HPLC were 
carried out. 
 
2. We studied 54 patients with newly-diagnosed CRC between September 2007 and 
September 2009. The diagnosis of CRC was confirmed on the basis of endoscopy and 
histology. We excluded patients who suffered from diseases, conditions and were using 
medications which can modify the urinary albumin excr tion. We did not exclude patients 
with diabetes mellitus (DM), and/or with hypertension (HT) and patients were treating with 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB) 
and/or diuretics. Finally a study with 38 CRC patien s was performed. As controls, 36 
volunteers were examined who were adjusted for age,DM, HT and also for taking ACE 
inhibitors, ARB and diuretics. Routine laboratory measurements and first morning urine 
samples analyses by means of IT and HPLC were carried out. 
 
3. We analyzed the data of 8783 patients who underwent an upper gastrointestinal 
endoscopical examination between 1996 and 2008. We det rmined the number of patients 
with CRF and GAVE and summarized the observations with OPPs.  
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4. RESULTS 
 
1. Patients with CD and UC had significantly higher albumin-creatinine ratio (ACR) 
determined by IT and HPLC than did the healthy controls (p<0.05).  
In CD, HPLC-ACR was significantly higher than IT-ACR in the active and inactive groups, 
as well (p<0.01). Using both IT and HPLC, higher ACR was measured in patients with active 
CD compared with patients with inactive CD (p<0.01) In addition, inactive patients 
(classified according to the Crohn’s Disease Activity Index /CDAI/ and the modified Harvey-
Bradshaw /H-B/ Activity Index) had higher albuminuria (measured either with HPLC or IT) 
than controls (p<0.001 for all). ROC curve analysis was carried out to select an appropriate 
cut-off value to predict likelihood of the clinical disease activity. These cut-off values were 
determined for IT-ACR and also for HPLC-ACR (IT-ACR in men was 0.37 mg/mmol, in 
women 1.62 mg/mmol, HPLC-ACR in men 2.46 mg/mmol, in women 5.30 mg/mmol) and 
their sensitivity and specificity were identified for the modified H-B Activity Index and 
CDAI. 
In patients with UC, only IT-ACR was significantly higher in patients with active compared 
to inactive UC diseases as judged by the modified H-B Activity Index (p<0.01). HPLC-ACR 
did not differ between active and inactive cases. When grouping UC patients according to 
activity upon the Colitis Activity Index (CAI), neither IT- nor HPLC-ACR differ between 
active and inactive cases, but by using the HPLC method significantly higher ACR could be 
detected compared to IT-ACR in both disease activity scores (the modified H-B Activity 
Index and CAI) (p<0.01). 
The correlations between HPLC-ACR and disease duration was not significant neither in CD 
nor in UC. Similarly, no correlation was found betwen MAU and disease extent (Montreal 
E) in UC. On the other hand, in CD, significant correlation was detected between MAU and 
disease extent (Montreal L). Patients with Montreal L3 had higher HPLC-ACR [8.51 (4.29-
12.58) mg/mmol] compared to Montreal L1 [3.59 (3.09-4.30) mg/mmol] or L2 [1.90 (1.63-
2.36) mg/mmol] [p<0.01 for both, data given as median (25-75 percentile)]. Only five patients 
had L4 i.e. upper gastrointestinal tract (GIT) manifestation, these patients tended to have 
higher albuminuria than patients without upper GIT manifestation, but the difference was not 
statistically significant. 
In CD, we found significant correlations between HPLC-ACR and some inflammatory 
markers i.e. white blood cell (WBC) count (r=0.257; p= 0.047) and erythrocyte sedimentation 
rate (ESR) (r=0.262; p= 0.047). The correlation betwe n HPLC-ACR and high-sensitivity C 
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reactive protein (hs-CRP) was not significant. In UC, there was no significant correlation 
between HPLC-ACR and the above markers of systemic inflammation. 
Stepwise linear regression analysis was carried out in patients with CD to find predictors of 
clinical activity scores (the modified H-B Activity Index and CDAI). We tested a model 
including duration of disease, platelet count (PLT), WBC, ESR, hs-CRP, urinary IT-ACR, 
and urinary HPLC-ACR as independent variables and the modified H-B Activity Index as a 
dependent variable. Independent predictors of the modified H-B Activity Index were duration 
of disease, hs-CRP and urinary HPLC-ACR (adjusted r2=0.562; duration of disease: ß=0.542, 
p<0.001; hs-CRP: ß=0.423, p=0.001; urinary HPLC-ACR: ß=0.269, p=0.036). We also tested 
the same linear regression model using CDAI as a dependent variable. Independent predictors 
of the CDAI were duration of disease, hs-CRP and urinary HPLC-ACR (adjusted r2=0.511; 
duration of disease: ß=0.536, p<0.001; hs-CRP: ß=0.341, p=0.010; urinary HPLC-ACR: 
ß=0.284, p=0.036). In addition, stepwise linear regession analysis with the suspected activity 
markers was carried out in patients with CD to find predictors of clinical activity scores. We 
tested a model including HPLC-ACR, ESR, hs-CRP, WBC, PLT as independent variables and 
the modified H-B Activity Index as a dependent variable. Independent predictor of the 
modified H-B Activity Index was HPLC-ACR (adjusted r2=0.202; p<0.001). We also tested 
the same linear regression model including IT-ACR, ESR, hs-CRP, WBC, PLT as 
independent variables and the modified H-B Activity Index as a dependent variable. 
Independent predictor of the modified H-B Activity Index was IT-ACR (adjusted r2=0.123; 
p<0.017). When we tested a model including HPLC-ACR, IT-ACR, ESR, hs-CRP, WBC and 
PLT as independent variables, independent predictor of the modified H-B Activity Index was 
HPLC-ACR (adjusted r2=0.252; p=0.001). When we searched for the independent predictor of 
CDAI, we tested a model including HPLC-ACR, ESR, hs-CRP, WBC, PLT as independent 
variables. Independent predictor of the CDAI was HPLC-ACR (adjusted r2=0.307; p=0.001). 
We also tested a linear regression model including IT-ACR, ESR, hs-CRP, WBC, PLT as 
independent variables and the CDAI as a dependent variable. Independent predictor of the 
CDAI was IT-ACR (adjusted r2=0.234; p=0.015). When we tested a model including both 
HPLC-ACR and IT-ACR beneath ESR, hs-CRP, WBC and PLT as independent variables, 
independent predictor of the CDAI was HPLC-ACR (adjusted r2=0.342; p=0.003). 
No similar analysis was carried out in UC patients as we found no significant correlations 
between urinary HPLC-ACR, IT-ACR and clinical scores. 
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2. Patients with CRC had significantly higher ACR determined by IT and HPLC than did the 
controls adjusted for age, DM, HT, taking ACE inhibitors, ARB and diuretics (p<0.05). 
HPLC-ACR was significantly higher than IT-ACR in patients with CRC and in controls as 
well (p<0.01). 
There were no correlations between ACR measured either with HPLC or IT and the stage of 
CRC or between ACR measured either with HPLC or IT and carcinoembrional antigen, 
CA19-9, ESR, hs-CRP, serum hemoglobin, iron, transferrin, transferrin saturation, ferritin, 
aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline 
phosphatase, gamma-glutamyl transpeptidase, total protein, albumin, total cholesterol, HDL-
cholesterol, creatinine, estimated glomerular filtration calculated by the Modification of Diet 
in Renal Disease (MDRD) formula. In patients with CR  significant correlations could be 
detected between IT-ACR and red blood cell (RBC) count (r=-0.546; p=0.001), hematocrit 
(HCT) (r=-0.389; p=0.030) and blood urea nitrogen (r=0.368; p=0.042), as well. In addition, 
significant correlations were present between HPLC-ACR and RBC count (r=-0.456; 
p=0.009), LDL-cholesterol (r=-0.411; p=0.022) and triglyceride (TG) (r=-0.524; p=0.002) 
serum level. The correlation between ACR and RBC count was independent from age, renal 
function, iron, transferrin, transferrin saturation a d ferritin level. There was no correlation 
between RBC count and renal function, serum iron level, vitamin B12 level, and hs-CRP. 
Significant correlations could be detected between RBC count and both MAU and folic acid 
level (r=0.340; p=0.042). 
Stepwise linear regression analysis was carried out in patients with CRC. We tested a model 
including HCT, RBC count and renal function as independent variables and the IT-ACR as a 
dependent variable. Independent predictor of IT-ACR was RBC count (β=-0.540; p=0.002). 
We also tested a linear regression model using RBC count, LDL-cholesterol, TG and 
phosphate as independent variables and the HPLC-ACR as a dependent variable. Independent 
predictor of HPLC-ACR was TG (β=-0.466; p=0.014). 
 
3. In our clinic, 8783 patients underwent an upper gastrointestinal endoscopical examination 
between 1996 and 2008. Out of these cases, 18 patients w re diagnosed with GAVE (0.2%). 
This date is similar to the international prevalence data. Four of the 14 patients had CRF. Two 
patients were treated with APC, two patients with GAVE and diffuse localized TLs were 
treated with OPP which successfully decreased the blood transfusion demand. 
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5. DISCUSSION 
 
1. MAU can be a marker of disease activity in IBD. The cause of MAU in IBD can be the 
increased citokin level provoked by systhemic inflammation. The increased citokin level can 
result in increased glomerular permeability. Using both IT and HPLC, higher ACR was 
measured in patients with CD compared with healthy volunteers, and higher ACR was 
measured in patients with active compared with inact ve CD. Measurement of albuminuria 
using HPLC is a more sensitive method detecting the dis ase activity in CD than the 
immunological method (IT). Above the IT- and HPLC-ACR cut off values calculated by 
means of ROC curve analysis the likelihood of the clinical disease activity is high. 
In UC, ACR is not a good marker of disease activity. Only IT-ACR was significantly higher 
in patients with active compared to inactive UC diseases as judged by the modified H-B 
Activity Index. Measurement of albuminuria using HPLC is a more sensitive method 
detecting the disease activity also in UC than the immunological method (IT). 
The correlation between HPLC-ACR and disease duration was not significant neither in CD 
nor in UC. Similarly, no correlation was found betwen MAU and disease extent in UC. On 
the other hand, significant correlation was detected b tween MAU and disease extent in CD. 
In CD, we found a significant correlation between HPLC-ACR and some inflammatory 
markers i.e. WBC count and ESR. The correlation betwe n HPLC-ACR and hs-CRP in CD 
was not significant. In UC, there was no significant correlation between HPLC-ACR and the 
above markers of systemic inflammation. 
In CD, by means of stepwise linear regression analysis when it included duration of disease, 
PLT, WBC, ESR, hs-CRP, urinary IT-ACR, and urinary HPLC-ACR as independent 
variables and the modified H-B Activity Index as a dependent variable, independent 
predictors of the modified H-B Activity Index were duration of disease, hs-CRP and urinary 
HPLC-ACR. When we also tested the same linear regression model using CDAI as a 
dependent variable, independent predictors of the CDAI were duration of disease, hs-CRP and 
urinary HPLC-ACR. When we tested a model including PLT, WBC, ESR, hs-CRP, urinary 
IT-ACR and urinary HPLC-ACR as independent variables and both activity indices (the 
modified H-B Activity Index and CDAI) as dependent variables, independent predictors of 
the activity indices were urinary HPLC-ACR and IT-ACR. No similar analysis was carried 
out in UC patients as we found no significant correlation between urinary HPLC-ACR, IT-
ACR and clinical scores. 
 9 
2. MAU can be a sensitive marker of CRC without any correlation with the stage of the 
disease. Measurement of albuminuria using HPLC is a more sensitive method detecting the 
CRC than the immunological method (IT). We tested a model including HCT, RBC count and 
renal function as independent variables and the IT-ACR as a dependent variable. Independent 
predictor of IT-ACR was RBC count. We also tested a linear regression model using RBC 
count, LDL-cholesterol, TG and phosphate as independent variables and the HPLC-ACR as a 
dependent variable. Independent predictor of HPLC-ACR was TG. 
We found no correlation between MAU and classical inflammatory markers in patients with 
CRC, which means that in these patients development of MAU does not only depend on 
inflammatory mechanisms. 
 
3. GAVE as a vascular malformation is a rare cause of upper gastrointestinal bleeding. It is an 
important lesion because it can cause an occult chronic or severe acute bleeding. This lesion is 
relatively common in patients with CRF. In these patients this lesion can be seen with diffuse 
TLs and OPP can be used (instead of endoscopical and surgical methods) to reduce blood 
transfusion demand.  
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6. THESES 
 
1/1. We justified that microalbuminuria is a simple and useful marker in disease activity of 
Crohn’s disease. 
1/2. In Crohn’s disease, we found a significant correlation between microalbuminuria and 
disease extent, but no correlation can be found between microalbuminuria and disease 
duration. 
1/3. We found that high-performance liquid chromatography is more sensitive than 
immunological method in detection of disease activity of inflammatory bowel diseases. 
2/1. We justified that microalbuminuria is a sensitive marker of the presence of colorectal 
cancer.  
2/2. We detected no correlation between microalbuminuria and the stage of colorectal cancer.  
2/3. We found that high-performance liquid chromatography is more sensitive than 
immunological method in detecting of microalbuminura in colorectal cancer. 
3/1. We found that gastric antral vascular ectasia and diffuse localised teleangiectatic lesions 
in patients with chronic renal failure can be successfully treated by means of oestrogen-
progesteron products. They can reduce the blood transfusion demand.  
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